Skip to main content

Tectonic Therapeutic, Inc 10-Q for FY2026 Q3

Tectonic Therapeutic, Inc. (TECX)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

Tectonic Therapeutic, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Tectonic Therapeutic completed TX45’s APEX Phase 2 enrollment with 191 patients across 14 countries in June 2026 and expects topline results by the end of January 2027. The IDMC recommended continuing the study without modification. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$21.35M
compared with a net loss of $19.04M a year earlier
Diluted EPS
-$1.08
compared with -$1.02 a year earlier